Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.01
    -0.05 (-2.66%)

    Market Cap: $163.54M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Niagen Bioscience, Inc. (NAGE) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Niagen Bioscience (NAGE) to earn $0.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $118.41M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.08.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy6100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates rise 15.8%.

    Fiscal year ending Dec 31, 2026
    $0.02
    EPS consensus, revenue $118.41M
    Fiscal year ending Dec 31, 2027
    -$0.08
    EPS consensus, revenue $137.10M
    Next report
    Mar 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.02$0.02 to $0.021$118.41M$117.90M to $118.83M5
    Dec 31, 2027-$0.08-$0.08 to -$0.081$137.10M$127.10M to $145.00M6

    Quarterly Estimates

    The EPS consensus falls from -$0.01 for the quarter ending Dec 31, 2026 to -$0.02 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.01-$0.05 to $0.028$30.52M$28.91M to $31.90M8
    Mar 31, 2027-$0.02-$0.02 to -$0.021$31.49M$29.20M to $33.45M4

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 77.8% from $0.09.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.02N/A$0.09$0.09$0.09-77.8%
    Fiscal year ending Dec 31, 2027-$0.08-$0.06$0.10$0.10$0.10N/A
    Quarter ending Mar 31, 2027-$0.02N/A$0.02$0.02$0.02N/A

    Frequently Asked Questions About NAGE

    What is the NAGE stock forecast?

    Consensus analyst estimates put Niagen Bioscience's EPS at $0.02 for the fiscal year ending Dec 31, 2026, on revenue of $118.41M. The consensus rating from 6 analysts is Buy.

    How do analysts rate NAGE stock?

    Of 6 analysts covering Niagen Bioscience, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NAGE next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.02, with estimates from $0.02 to $0.02 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.08 to -$0.08 from 1 analyst.

    What revenue do analysts expect from Niagen Bioscience next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $118.41M, with estimates from $117.90M to $118.83M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $137.10M, with estimates from $127.10M to $145.00M.

    How many analysts cover NAGE?

    6 analysts rate Niagen Bioscience stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.